Developing vaccines that get ahead of pathogenic mutations and protect against the next coronavirus pandemic is one of the aims of the new Oxford, UK-based vaccine development company, ConserV Bioscience. The firm also has a pipeline of preclinical and clinical vaccine candidates for conditions such as mosquito-borne infections, rotavirus and Chagas.
Spun out of the UK life sciences company incubator, SEEK in 2020, ConserV Bioscience’s COVID-19 technology is focused...